Core Viewpoint - The company, Ruian Gene, is facing significant legal challenges due to the arrest and prosecution of its actual controllers, Xiong Hui and Xiong Jun, for fraud. Despite these issues, the company asserts that its daily operations will not be adversely affected, as it has a robust governance structure and management team in place [1][2]. Financial Performance - For the fiscal year 2024, the company reported a revenue of 242.31 million yuan, with a total profit of -28.47 million yuan and a net profit attributable to the parent company of -15.76 million yuan. The net profit, after excluding non-recurring gains and losses, was -19.25 million yuan [2][3]. - The company anticipates a revenue of 170 million to 176 million yuan for the year 2025, with expected net losses ranging from 39.91 million to 59.86 million yuan. The net profit, after excluding non-recurring items, is projected to be a loss of 49.91 million to 69.86 million yuan [2]. Operational Challenges - The company experienced a significant decline in net profit attributable to the parent company, with a year-on-year revenue decrease of approximately 66.31 million to 72.31 million yuan, representing a reduction of 27.36% to 29.84%. This decline is attributed to intensified industry competition, slower customer payments leading to credit impairment losses, and a halt in the development of its molecular diagnostic reagent center [3].

Core Viewpoint - Ruiang Gene's actual controllers, Xiong Hui and Xiong Jun, are facing legal action for fraud, which has been officially filed by the prosecution [2][4]. Group 1: Legal Issues - Ruiang Gene announced that its actual controllers, Xiong Hui and Xiong Jun, have been sued for fraud by the prosecution [2]. - Both individuals were previously detained and are now facing formal charges [4]. - The company stated that Xiong Hui and Xiong Jun do not hold any current positions as directors or senior management, and this situation is not expected to significantly impact the company's daily operations [4]. Group 2: Company Management Changes - Gao Shangxian has taken over as chairman and general manager, succeeding Xiong Hui, who is his spouse [4]. - The actual controllers of Ruiang Gene include Xiong Hui, Gao Shangxian, Xiong Jun, and Gao Ze, collectively holding 30.62% of the company's shares [5][6]. Group 3: Financial Performance - Ruiang Gene reported a net loss of 15.76 million yuan in 2024, a decrease of 298.78% compared to the previous year [6][7]. - The company anticipates a further net loss for 2025, estimated between 39.91 million yuan and 59.86 million yuan [6]. - The decline in revenue is attributed to intensified competition in the in vitro diagnostics industry, slower customer payments, and the suspension of certain projects [7].

Core Viewpoint - The resignation of the chairman and key personnel of Ruian Gene Technology Co., Ltd. raises concerns about the company's leadership and ongoing operations, but the company asserts that daily operations and technical research remain normal [1][3]. Group 1: Leadership Changes - Chairman Xiong Hui has resigned from her positions as chairman, director, general manager, and core technical personnel due to personal reasons, but will continue to hold other roles within the company [1][3]. - Xiong Hui's husband, Gao Shangxian, will take over the position of chairman following her resignation [3]. Group 2: Legal Issues - In July 2024, Xiong Hui and other key personnel were placed under residential surveillance due to suspected illegal operations, with some later facing criminal detention [5]. - By October 2024, the charges against Xiong Hui and others were changed to fraud, and by December 2024, they were formally arrested, with the case entering the prosecution phase [5]. Group 3: Company Overview - Ruian Gene was established in 2012 and specializes in the research, production, and sales of in vitro diagnostic products, including testing instruments and reagents [5]. - The company provides precise genetic and antigen testing for patients with blood diseases, solid tumors, and infectious diseases [5].

Core Viewpoint - The resignation of Xiong Hui, the chairman of Ruian Gene, raises concerns about the company's leadership and ongoing operations, although she remains the actual controller of the company [3][4]. Group 1: Leadership Changes - Xiong Hui has resigned from her positions as chairman, director, general manager, and core technical personnel due to personal reasons, but will continue to hold other roles within the company [1][3]. - Gao Shangxian, Xiong Hui's husband, will take over the chairman position following her resignation [3]. Group 2: Legal Issues - Xiong Hui and other key personnel have been subjected to criminal detention for alleged fraud, with the case currently under review by the prosecution [2][6]. - The legal troubles may be linked to a fraud case involving AstraZeneca, where there were allegations of falsifying genetic testing reports for insurance reimbursement [6][7]. Group 3: Company Background - Ruian Gene, established in 2012, specializes in the research, production, and sales of in vitro diagnostic products, focusing on precision testing for blood diseases, solid tumors, and infectious diseases [4]. - The actual controllers of the company include Xiong Hui, Gao Shangxian, Xiong Jun, and Gao Ze, collectively holding 30.62% of the company's shares [4]. Group 4: Financial Performance - In the first half of 2025, Ruian Gene reported a revenue of 105 million yuan, a decrease of 22.29% year-on-year, and a net profit attributable to shareholders of 3.55 million yuan, down 61.46% year-on-year [7].